Preclinical evaluation of VAX-IP, a novel bacterial minicell-based biopharmaceutical for nonmuscle invasive bladder cancer

The development of new therapies that can prevent recurrence and progression of nonmuscle invasive bladder cancer remains an unmet clinical need. The continued cost of monitoring and treatment of recurrent disease, along with its high prevalence and incidence rate, is a strain on healthcare economic...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Ther Oncolytics
Autors principals: Tsuji, Shingo, Chen, Xuguang, Hancock, Bryan, Hernandez, Veronica, Visentin, Barbara, Reil, Katherine, Sabbadini, Roger, Giacalone, Matthew, Godbey, WT
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4824562/
https://ncbi.nlm.nih.gov/pubmed/27119118
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mto.2016.4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars